FROM THE HEADLINES: 2012 Symposium Speaker Dr. Raja Flores on the Lasting Toll of 9-11

Dr. Raja Flores, chief of thoracic surgery at Mount Sinai School of Medicine and a featured speaker at our 2012 Symposium in Washington D.C., spoke to FoxNews.com about the adverse health effects some of those first responders have faced. The article reports that Mount Sinai researchers have been following approximately 30,000 first responders, many of whom were breathing in dust containing 2,000 tons of asbestos on a daily basis as they cleaned up the site. The researchers found 30 percent had problems with asthma, 40 percent had sinus problems, and another 40 percent had gastro-esophageal reflux, which is a precursor to esophageal cancer.

You can also watch the accompanying video here.

If you want to hear more from Dr. Flores, make plans to join us at the 2012 Symposium on Thursday, July 12, (9:45 a.m. – 12:00 Noon) to participate in the panel “Demystifying Scientific Breakthroughs” panel. Along with Dr. Flores,  the latest in mesothelioma research will be presented by Stephen Hahn, MD, Raffit Hassan, MD, Robert Kratzke, MD, Harvey Pass, MD, Daniel Sterman, MD, David Sugarbaker, MD.

Click here to preview the 2012 Symposium agenda.

FROM THE HEADLINES: The Mesothelioma Applied Research Foundation Appears before the United States Senate Committee on Appropriations

Last week, on June 6, 2012, Mary Hesdorffer, MS, APRN, nurse practitioner and medical liaison for the Mesothelioma Applied Research Foundation, appeared before the United States Senate Committee on Appropriations – Subcommittee on Defense, at their Fiscal Year 2013 Appropriations Outside Witness Testimony Hearing. Speaking with the voice of the Meso Foundation and its community, Mary made an appeal to the lawmakers for their attention concerning mesothelioma and its impact on those who served to defend the United States.

The Meso Foundation played a critical role in making peritoneal mesothelioma and pleural mesothelioma eligible topics within the Congressionally Directed Medical Research Program. The first ever DoD award for mesothelioma occurred in 2008 when one investigator obtained over $1.3 million for research. A total of $7.7 million has been awarded to mesothelioma research through the Peer Reviewed Medical Research Program and the Peer Reviewed Cancer Research Program, both divisions of the Congressionally Directed Medical Research Program, which is administered by the Department of Defense since Fiscal Year 2008. Continue reading “FROM THE HEADLINES: The Mesothelioma Applied Research Foundation Appears before the United States Senate Committee on Appropriations” »

FROM THE HEADLINES: Photodynamic Therapy Added to Lung-Sparing Surgery Improves Survival for Mesothelioma Patients

The website Medical News Today recently released findings of a new treatment for patients with malignant pleural mesothelioma. The treatment involves PDT (photodynamic therapy) conjunction with lung-sparing surgery. Results look promising in comparison to patients utilizing other mesothelioma treatment options. In this approach, provided the patient can keep both lungs after treatment, patients face better chances in combatting mesothelioma once it returns. Patient are given a photosensitive drug that cancer cells absorb, and then Fiber optics direct light onto the tumor site, which activates the drugs, and destroys the cancerous cells.

Leading this research from the Perelman School of Medicine, University of Pennsylvania, is Dr. Joseph Friedberg, MD. In this battle against mesothelioma, considered one of the most aggressive forms of cancer, Dr. Friedberg has stated, ”While I don’t consider anything short of a cure as a victory against mesothelioma, I am encouraged by our results. Based on our new findings, we are redoubling our clinical and translational research efforts to find a way to further improve and refine this multimodality treatment approach for mesothelioma.” Continue reading “FROM THE HEADLINES: Photodynamic Therapy Added to Lung-Sparing Surgery Improves Survival for Mesothelioma Patients” »